223 related articles for article (PubMed ID: 22014687)
1. Unexpected recombinations in single chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module.
Stamova S; Cartellieri M; Feldmann A; Arndt C; Koristka S; Bartsch H; Bippes CC; Wehner R; Schmitz M; von Bonin M; Bornhäuser M; Ehninger G; Bachmann M
Mol Immunol; 2011 Dec; 49(3):474-82. PubMed ID: 22014687
[TBL] [Abstract][Full Text] [Related]
2. Generation of single-chain bispecific green fluorescent protein fusion antibodies for imaging of antibody-induced T cell synapses.
Stamova S; Feldmann A; Cartellieri M; Arndt C; Koristka S; Apel F; Wehner R; Schmitz M; Bornhäuser M; von Bonin M; Ehninger G; Bartsch H; Bachmann M
Anal Biochem; 2012 Apr; 423(2):261-8. PubMed ID: 22274538
[TBL] [Abstract][Full Text] [Related]
3. Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33 and CD16.
Singer H; Kellner C; Lanig H; Aigner M; Stockmeyer B; Oduncu F; Schwemmlein M; Stein C; Mentz K; Mackensen A; Fey GH
J Immunother; 2010; 33(6):599-608. PubMed ID: 20551837
[TBL] [Abstract][Full Text] [Related]
4. Single-chain mono- and bispecific antibody derivatives with novel biological properties and antitumour activity from a COS cell transient expression system.
Hayden MS; Linsley PS; Gayle MA; Bajorath J; Brady WA; Norris NA; Fell HP; Ledbetter JA; Gilliland LK
Ther Immunol; 1994 Jan; 1(1):3-15. PubMed ID: 7584477
[TBL] [Abstract][Full Text] [Related]
5. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
[TBL] [Abstract][Full Text] [Related]
6. Effect of linker sequences between the antibody variable domains on the formation, stability and biological activity of a bispecific tandem diabody.
Le Gall F; Reusch U; Little M; Kipriyanov SM
Protein Eng Des Sel; 2004 Apr; 17(4):357-66. PubMed ID: 15126676
[TBL] [Abstract][Full Text] [Related]
7. A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting.
Kügler M; Stein C; Kellner C; Mentz K; Saul D; Schwenkert M; Schubert I; Singer H; Oduncu F; Stockmeyer B; Mackensen A; Fey GH
Br J Haematol; 2010 Sep; 150(5):574-86. PubMed ID: 20636437
[TBL] [Abstract][Full Text] [Related]
8. Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.
Holliger P; Manzke O; Span M; Hawkins R; Fleischmann B; Qinghua L; Wolf J; Diehl V; Cochet O; Winter G; Bohlen H
Cancer Res; 1999 Jun; 59(12):2909-16. PubMed ID: 10383154
[TBL] [Abstract][Full Text] [Related]
9. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
Chen J; Zhou JH; Ball ED
Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
[TBL] [Abstract][Full Text] [Related]
10. Engineering a CD123xCD3 bispecific scFv immunofusion for the treatment of leukemia and elimination of leukemia stem cells.
Kuo SR; Wong L; Liu JS
Protein Eng Des Sel; 2012 Oct; 25(10):561-9. PubMed ID: 22740616
[TBL] [Abstract][Full Text] [Related]
11. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
12. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
[TBL] [Abstract][Full Text] [Related]
13. Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells.
Arndt C; von Bonin M; Cartellieri M; Feldmann A; Koristka S; Michalk I; Stamova S; Bornhäuser M; Schmitz M; Ehninger G; Bachmann M
Leukemia; 2013 Apr; 27(4):964-7. PubMed ID: 23325142
[No Abstract] [Full Text] [Related]
14. [Construction, expression and functional characterization of single chain variable fragments (scFv) against human CD33 antigen].
Chen XJ; Wang Y; Qu H; Ge XS; Zuo YF; Liao XL
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2007 Dec; 23(12):1147-9. PubMed ID: 18062889
[TBL] [Abstract][Full Text] [Related]
15. Biologic properties of a bispecific single-chain antibody directed against 17-1A (EpCAM) and CD3: tumor cell-dependent T cell stimulation and cytotoxic activity.
Mack M; Gruber R; Schmidt S; Riethmüller G; Kufer P
J Immunol; 1997 Apr; 158(8):3965-70. PubMed ID: 9103467
[TBL] [Abstract][Full Text] [Related]
16. T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct.
Aigner M; Feulner J; Schaffer S; Kischel R; Kufer P; Schneider K; Henn A; Rattel B; Friedrich M; Baeuerle PA; Mackensen A; Krause SW
Leukemia; 2013 Apr; 27(5):1107-15. PubMed ID: 23178753
[TBL] [Abstract][Full Text] [Related]
17. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics.
Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I
MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309
[TBL] [Abstract][Full Text] [Related]
18. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
[TBL] [Abstract][Full Text] [Related]
19. Characterization of CD33/CD3 Tetravalent Bispecific Tandem Diabodies (TandAbs) for the Treatment of Acute Myeloid Leukemia.
Reusch U; Harrington KH; Gudgeon CJ; Fucek I; Ellwanger K; Weichel M; Knackmuss SH; Zhukovsky EA; Fox JA; Kunkel LA; Guenot J; Walter RB
Clin Cancer Res; 2016 Dec; 22(23):5829-5838. PubMed ID: 27189165
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways.
Balaian L; Ball ED
Exp Hematol; 2005 Feb; 33(2):199-211. PubMed ID: 15676214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
